Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:37:35.294Z.
Consensus retrieved: 2026-10-06T12:48:37.428Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:37:35.294Z.
Quote observation: 2026-10-06T16:35:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a84589f7b73c5fc7448e1a11526b61c4e763dd9c6e5f877a8586f943b51ec8b
Forward PE Ratio (N/A) = Dated Quote Price ($1.15) / Consensus Forward EPS ($-0.76)
FORWARD PE RATIO
N/A
Inovio Pharmaceuticals, Inc.
Market Cap
$79.45M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | $79.45M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $79.82M | N/A |
| Pulmonx Corporation (LUNG)vs › | $78.14M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.05M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.81M | 8.80 |
| Nutriband Inc. (NTRB)vs › | $82.05M | 4.30 |
| MediciNova, Inc. (MNOV)vs › | $82.45M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.58M | N/A |
| Outset Medical, Inc. (OM)vs › | $76.00M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.91M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.15, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.76 | $-0.77 – $-0.75 | 2 | n/m |
| 2027-12-31 | $-0.43 | $-0.65 – $-0.20 | 2 | n/m |
| 2028-12-31 | $-0.10 | $-0.14 – $-0.05 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
